These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Receptor Binding Domains of TcdB from Henkel D; Tatge H; Schöttelndreier D; Tao L; Dong M; Gerhard R Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255261 [TBL] [Abstract][Full Text] [Related]
5. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. Merrigan M; Venugopal A; Mallozzi M; Roxas B; Viswanathan VK; Johnson S; Gerding DN; Vedantam G J Bacteriol; 2010 Oct; 192(19):4904-11. PubMed ID: 20675495 [TBL] [Abstract][Full Text] [Related]
6. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response. Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251 [TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616 [TBL] [Abstract][Full Text] [Related]
9. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481 [TBL] [Abstract][Full Text] [Related]
10. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection. Wang S; Heuler J; Wickramage I; Sun X Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695 [TBL] [Abstract][Full Text] [Related]
11. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections. Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121 [TBL] [Abstract][Full Text] [Related]
12. Expression and (Lacking) Internalization of the Cell Surface Receptors of Schöttelndreier D; Seeger K; Grassl GA; Winny MR; Lindner R; Genth H Front Microbiol; 2018; 9():1483. PubMed ID: 30022975 [TBL] [Abstract][Full Text] [Related]
13. Sequence variation in tcdA and tcdB of Clostridium difficile: ST37 with truncated tcdA is a potential epidemic strain in China. Du P; Cao B; Wang J; Li W; Jia H; Zhang W; Lu J; Li Z; Yu H; Chen C; Cheng Y J Clin Microbiol; 2014 Sep; 52(9):3264-70. PubMed ID: 24958798 [TBL] [Abstract][Full Text] [Related]
14. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection. Wang S; Zhu D; Sun X Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336 [TBL] [Abstract][Full Text] [Related]
15. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection. Chen P; Zeng J; Liu Z; Thaker H; Wang S; Tian S; Zhang J; Tao L; Gutierrez CB; Xing L; Gerhard R; Huang L; Dong M; Jin R Nat Commun; 2021 Jun; 12(1):3748. PubMed ID: 34145250 [TBL] [Abstract][Full Text] [Related]
16. Protease-stable DARPins as promising oral therapeutics. Simeon RA; Zeng Y; Chonira V; Aguirre AM; Lasagna M; Baloh M; Sorg JA; Tommos C; Chen Z Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34882774 [TBL] [Abstract][Full Text] [Related]
17. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. LaFrance ME; Farrow MA; Chandrasekaran R; Sheng J; Rubin DH; Lacy DB Proc Natl Acad Sci U S A; 2015 Jun; 112(22):7073-8. PubMed ID: 26038560 [TBL] [Abstract][Full Text] [Related]
18. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab. Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034 [TBL] [Abstract][Full Text] [Related]
19. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518 [TBL] [Abstract][Full Text] [Related]
20. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains. Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]